DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
By HealthVetted Editorial
Reviewed & updated
Whether insurance covers a GLP-1 medication comes down to two things more than anything else: the specific plan you have, and the reason it's being prescribed. The same drug molecule can be covered for one person and denied for another, because coverage often hinges on the FDA-approved use the prescription is tied to.
GLP-1 medications are prescribed in two broad lanes: type 2 diabetes and chronic weight management. Plans frequently treat these very differently. A medication framed around diabetes is often easier to get covered than the same class of drug framed around weight loss. That distinction is the single biggest driver of whether your claim is approved.
This is general information, not medical advice. Coverage rules change, and decisions about whether a GLP-1 is right for you belong with your clinician and your insurer. For broader context on the medications themselves, start with the [GLP-1 weight loss](/glp-1-weight-loss) pillar.
The active ingredients overlap across brand names, but the FDA approvals do not. Semaglutide and tirzepatide are each sold under different brand names depending on the approved use:
| Active ingredient | Diabetes brand | Weight-management brand |
|---|---|---|
| Semaglutide | Ozempic | Wegovy |
| Tirzepatide | Mounjaro | Zepbound |
Ozempic and Mounjaro are approved for type 2 diabetes. 56 Wegovy and Zepbound are approved for chronic weight management. 34 Insurers read these approvals closely. A plan may cover a diabetes-indicated product readily while excluding, restricting, or requiring extra hurdles for a weight-management product — even though the underlying clinical effect on weight can be similar. The weight-loss data is substantial: in trials, semaglutide produced roughly 15% average body-weight reduction over 68 weeks 1 and tirzepatide roughly 21% over 72 weeks. 2 But clinical effectiveness and insurance coverage are separate questions.
Compare the two weight-management options side by side on the [Wegovy vs. Zepbound](/compare/wegovy-vs-zepbound) page, or read the individual breakdowns for [Wegovy](/reviews/wegovy) and [Zepbound](/reviews/zepbound).
Even when a GLP-1 is on your plan's covered drug list (the formulary), coverage rarely means "free." Several mechanisms shape what you'll pay and whether you qualify:
The practical upshot: read your plan's formulary and its coverage criteria before assuming anything.
Prior authorization (PA) is where most GLP-1 coverage decisions are made. Your clinician submits clinical information — often your BMI, weight-related conditions, and history of prior weight-management efforts — and the insurer decides whether the prescription meets its criteria.
To improve your odds:
Government coverage has historically treated weight-loss drugs differently from diabetes drugs. Medicare has long had statutory limitations around drugs used specifically for weight loss, while diabetes-indicated products have had a clearer path. Medicaid coverage varies by state.
Because these policies are actively evolving, do not assume current rules based on what you read even a year ago. The reliable move is to verify directly with the specific program and plan you're enrolled in, ideally in writing. We're intentionally not stating program-specific dollar figures or effective dates here, because those details shift and getting them from the source protects you.
A denial doesn't have to be the end of the road.
For a fuller cost breakdown, including out-of-pocket dynamics, see [best prescription GLP-1](/best-prescription-glp1). If you're weighing whether you even qualify, the [eligibility quiz](/tools/glp1-eligibility-quiz) can help you organize the questions to bring to your clinician.
Have these ready when you contact your plan:
Coverage for GLP-1 medications is genuinely inconsistent across plans, but it is also navigable. The patients who get covered are usually the ones who understand their own formulary, match the prescription to the right indication, and come to prior authorization prepared. Pair that diligence with a clear-eyed look at cost, and you'll know your real options before the first claim is ever filed.
Lifestyle still matters alongside any medication: resistance and aerobic activity support general health and help preserve muscle during weight loss. 10 Medication is one tool, not the whole plan. 78
Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management. Many plans cover diabetes-indicated drugs more readily than weight-management drugs, even though both contain semaglutide. The difference is driven by the FDA-approved use your prescription is tied to, not the molecule itself.
Medicare has historically had limitations around drugs used specifically for weight loss, while diabetes-indicated products have had a clearer path. These policies are evolving, so verify current rules directly with your specific Medicare plan in writing rather than relying on older information.
Prior authorization is a process where your prescriber submits clinical documentation — often your BMI, weight-related conditions, and treatment history — before the insurer agrees to pay. It is very common for GLP-1 medications. Coming prepared with eligibility documentation improves your chances of approval.
You can appeal the decision with help from your clinician, including a letter of medical necessity. You can also ask about an alternative covered product, look into manufacturer savings programs, or explore compounded options. Discuss any change in medication with your clinician rather than switching on your own.
Check your plan's formulary (covered drug list) and its coverage criteria. Have the exact brand name and intended indication ready, and ask whether prior authorization or step therapy applies, what tier the drug is on, and what the BMI and condition requirements are for weight-management coverage.